Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:1803-1811, doi:10.1016/j.jacc.2005.07.047 (Published online 18 October 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Only Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vicari, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vicari, R. M.

Efficacy and Safety of Fasudil in Patients With Stable Angina

A Double-Blind, Placebo-Controlled, Phase 2 Trial

Ralph M. Vicari, MD, FACC*,*, Bernard Chaitman, MD, FACC{dagger}, Deborah Keefe, MD, MPH, FACC{ddagger}, William B. Smith, MD, FACC§, Steven G. Chrysant, MD, PhD, FACC||, Melvin J. Tonkon, MD, FACC, Neville Bittar, MD, FACC#, Robert J. Weiss, MD, FACC**, Hugo Morales-Ballejo, MD, FACC{ddagger}, Udho Thadani, MBBS, MRCP, FRCPC, FACC{dagger}{dagger} for the Fasudil Study Group

* MIMA Century Research Associates, Melbourne, Florida
{dagger} St. Louis University, St. Louis, Missouri
{ddagger} Berlex, Inc., Montville, New Jersey
§ New Orleans Center for Clinical Research, New Orleans, Louisiana
|| Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma
Apex Research Institute, Santa Ana, California
# Gemini Scientific, Madison, Wisconsin
** Androscoggin Cardiology Associates, Auburn, Maine
{dagger}{dagger} VA Medical Center, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma



View larger version (10K):

[in a new window]
 
Figure 1 Schematic diagram of the study design. Exercise testing (X) was performed before dosing (trough), 1 h after dosing (peak), and 4 h after dosing of both fasudil and matching placebo tablets. tid = three times daily.

 


View larger version (27K):

[in a new window]
 
Figure 2 Patient disposition during the study.

 


View larger version (22K):

[in a new window]
 
Figure 3 Changes in exercise treadmill testing duration from baseline at peak for fasudil- (solid bars) and placebo-treated (open bars) patients (mean ± standard deviation). tid = three times daily.

 


View larger version (20K):

[in a new window]
 
Figure 4 Changes in mean time to ≥1 mm ST-segment depression from baseline for fasudil- (solid bars) and placebo-treated (open bars) patients. *p = 0.001. tid = three times daily.

 


View larger version (18K):

[in a new window]
 
Figure 5 Improvements in angina by ≥1 Canadian Cardiovascular Society angina class in patients treated with fasudil (solid bars) and placebo (open bars). tid = three times daily.

 


View larger version (18K):

[in a new window]
 
Figure 6 Improvement in Seattle Angina Questionnaire score. (A) Physical limitation scale. (B) Treatment satisfaction scale. *p < 0.05. tid = three times daily. Open bars = placebo; solid bars = fasudil.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement